“We are proud to advance into the next phase of our clinical journey for JANX007 and begin treating patients in our Phase 1b expansion studies,” said David Campbell, Ph.D., President and CEO of Janux. “We also look forward to our first R&D Day where we will unveil previously undisclosed preclinical programs that utilize our expertise and platform technologies to address significant unmet medical needs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Buy Rating for Janux Therapeutics Inc. Driven by Strategic Advancements in Prostate Cancer Treatment with JANX007
- Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation
- Buy Rating for Janux Therapeutics Inc: Promising Clinical Trial Results and Positive Outlook for JANX007
- Janux Therapeutics initiates expansion studies in ENGAGER-PSMA-01 trial
- Buy Rating for Janux Therapeutics: Promising Technology and Strong Financial Position Amid Competitive Pressure